Axcelis Technologies, Inc. (ACLS)

Orchard Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	173.65	123.51	167.3	185.6	294.92	203.48
Short-Term Investments	376.19	447.83	338.85	246.57	-	-
Cash & Short-Term Investments	549.84	571.34	506.15	432.17	294.92	203.48
Cash Growth	0.28%	12.88%	17.12%	46.53%	44.94%	45.47%
Receivables	138.84	203.15	217.96	169.77	104.41	86.87
Inventory	310.77	282.23	306.48	242.41	194.98	161.08
Prepaid Expenses	59.52	60.47	49.4	33.3	24.93	19.37
Other Current Assets	5.51	6.42	-	-	-	-
Total Current Assets	1,064	1,124	1,080	877.65	619.25	470.79
Property, Plant & Equipment	100.64	98.75	101.32	69.75	63.45	54.93
Long-Term Deferred Tax Assets	72.43	68.28	53.43	31.7	35.45	57.85
Long-Term Deferred Charges	-	45.17	36.92	30.24	32	38.46
Other Long-Term Assets	54.82	12.97	10.31	4.3	3.08	2.59
Total Assets	1,323	1,349	1,282	1,014	753.24	624.62
Accounts Payable	37.11	46.93	54.4	62.35	38.03	24.01
Accrued Expenses	16.63	25.54	31.45	35.54	30.73	24.56
Current Portion of Leases	1.44	5.82	6.49	6.6	5.7	3.33
Current Income Taxes Payable	-	-	6.16	4.3	0.89	0.65
Current Unearned Revenue	89.83	94.67	164.68	123.47	60.45	21.22
Other Current Liabilities	32.1	34.57	21.95	15.88	14.35	10.65
Total Current Liabilities	177.11	207.52	285.13	248.13	150.14	84.43
Long-Term Leases	41.57	67.65	69.4	52.12	50.77	49.34
Long-Term Unearned Revenue	39.92	43.5	46.21	31.31	7.98	1.84
Other Long-Term Liabilities	42.51	17.32	16.35	14.83	5.39	7.41
Total Liabilities	301.1	335.99	417.09	346.39	214.28	143.02
Common Stock	0.03	0.03	0.03	0.03	0.03	0.03
Additional Paid-In Capital	535.67	548.65	547.19	550.3	559.88	570.1
Retained Earnings	487.16	470.32	319.51	118.89	-22.72	-91.97
Comprehensive Income & Other	-0.48	-6.21	-1.85	-1.97	1.77	3.44
Shareholders' Equity	1,022	1,013	864.88	667.26	538.96	481.6
Total Liabilities & Equity	1,323	1,349	1,282	1,014	753.24	624.62
Total Debt	43	73.47	75.89	58.71	56.47	52.67
Net Cash (Debt)	506.84	497.88	430.26	373.45	238.46	150.81
Net Cash Growth	6.73%	15.72%	15.21%	56.61%	58.12%	76.10%
Net Cash Per Share	15.68	15.22	12.97	11.13	6.96	4.42
Filing Date Shares Outstanding	31.42	32.15	32.63	32.71	33.25	33.73
Total Common Shares Outstanding	31.42	32.37	32.69	32.78	33.24	33.63
Working Capital	887.37	916.09	794.86	629.51	469.11	386.36
Book Value Per Share	32.54	31.29	26.46	20.36	16.21	14.32
Tangible Book Value	1,022	1,013	864.88	667.26	538.96	481.6
Tangible Book Value Per Share	32.54	31.29	26.46	20.36	16.21	14.32
Land	-	25.81	21.8	18	15.88	10.89
Machinery	-	45.48	41.55	34.73	34.31	30.77
Construction In Progress	-	13.6	17.06	10.19	6.85	6.7
Order Backlog	-	645.8	1,061	-	-	-

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q